摘要
目的根据现有临床资料评估华蟾素注射液应用于介入治疗肝癌的临床疗效。方法利用Meta分析的方法综合国内2000—2008年华蟾素注射液介入治疗肝癌的临床研究文献10篇,评估治疗缓解率、有效率、1年生存率和2年生存率。结果肝癌病人的缓解率基本没有偏倚,有效率、1年生存率和2年生存率的比值比(OR)呈偏态分布;缓解率、有效率、1年生存率及2年生存率经异质性检验P值均大于0.05,可合并研究,采用固定效应模型。其合并OR分别为1.87、2.80、2.55和2.61,95%可信区间分别为1.39～2.52、1.96～3.99、1.90～3.42和1.96～3.48。治疗组的缓解率、有效率、1年生存率和2年生存率均高于对照组,有显著差异。结论华蟾素注射液应用于介入治疗肝癌是有效的。
AIM To evaluate the efficacy of cinobufacini injection in the treatment of hepatocellular carcinoma after transcatheter arterial chemoembolization （TACE）, based on available clinical data. METHODS Meta analysis was conducted on 10 studies about cinobufacini injection in hepatocellular carcinoma after TACE published from 2000 to 2008 in Chinese journals, and involved in relieve rate, effective rate, 1 year survival rate, and 2 year survival rate. RESULTS No publication bias was detected in relieve rate, and publication bias was detected in effective rate, 1 year survival rate, and 2 year survival rate. After the consistency check, all rates were homogenous （P 〉 0.05）, therefore, fixed effect model was applied. Odds ratio （OR） of relieve rate, effective rate, 1 year survival rate, and 2 year survival rate were 1.87, 2.80, 2.55, and 2.61, respectively, and 95% confidence interval were 1.39 - 2.52, 1.96 - 3.99, 1.90 - 3.42, and 1.96 - 3.48, respectively. The relieve rate, effective rate, 1 year survival rate, and 2 year survival rate of treatment group were significantly higher than those of the control group. CONCLUSION Cinobufacini injection is effective in the treatment of hepatocellular carcinoma after transcatheter arterial chemoembolization.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2009年第9期671-674,共4页
Chinese Journal of New Drugs and Clinical Remedies
基金
2008年度上海市医院药学科研基金--肿瘤药学专项(2008-YY-0224)
关键词
肝肿瘤
META分析
偏倚
华蟾素注射破
肝动脉介入化疗栓塞
liver neoplasms
Meta analysis
bias
cinobufacini injection
transcatheter arterial chemoembolization
